[Immunotherapy and cell therapy for myeloid leukemia]

Nihon Rinsho. 2009 Oct;67(10):1938-43.
[Article in Japanese]

Abstract

To develop effective cellular immunotherapy for hematopoietic malignancies, the tumor-associated antigens that are recognized by cytotoxic T lymphocytes (CTL) must be identified. Recently, various leukaemia-associated antigens that are recognized by CTL in the context of HLA class I molecules have been identified. These include fusion gene products such as BCR-ABL and ETV6-AML1, proteinase 3, WT1, human telomerase reverse transcriptase, cyclophilin B, and PRAME. In addition, various target antigens associated with other hematopoietic malignancies have been also identified. On the basis of these findings, various clinical trials of immunotherapy for hematological malignancies, including peptide vaccination, dendritic cell therapy, adoptive transfer of CTL, T-cell receptor gene therapy have been ongoing. Here, the current status and future feasibility of cellular immunotherapy for leukemia are discussed.

Publication types

  • English Abstract
  • Review

MeSH terms

  • Adoptive Transfer
  • Cancer Vaccines
  • Cell- and Tissue-Based Therapy / methods*
  • Core Binding Factor Alpha 2 Subunit / immunology
  • Dendritic Cells
  • Fusion Proteins, bcr-abl / immunology
  • Genetic Therapy
  • Humans
  • Immunotherapy / methods*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy*
  • Leukemia, Myeloid, Acute / therapy*
  • Myeloblastin / immunology
  • Oncogene Proteins, Fusion / immunology
  • Receptors, Antigen, T-Cell / genetics
  • T-Lymphocytes, Cytotoxic / immunology
  • Vaccines, Subunit
  • WT1 Proteins / immunology

Substances

  • Cancer Vaccines
  • Core Binding Factor Alpha 2 Subunit
  • Oncogene Proteins, Fusion
  • Receptors, Antigen, T-Cell
  • TEL-AML1 fusion protein
  • Vaccines, Subunit
  • WT1 Proteins
  • Fusion Proteins, bcr-abl
  • Myeloblastin